Skip to main content

Jennifer Doudna, Ph.D.

Dr. Doudna is a co-founder of Caribou and a faculty member of the departments of Molecular and Cell Biology and Chemistry at the University of California, Berkeley, and Lawrence Berkeley National Lab, is an investigator at the Howard Hughes Medical Institute, and is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Her research seeks to understand how non-coding RNA molecules control the expression of genetic information and she has published extensively in the field of CRISPR-Cas biology. Dr. Doudna’s work and that of her collaborator Emmanuelle Charpentier was recognized by the Nobel Prize and the Breakthrough Prize. Her work on CRISPR-Cas systems has also been recognized with the Paul Janssen Award for Biomedical Research and a Lurie Prize in Biomedical Sciences, and the Princess of Asturias award. Dr. Doudna was also named to the 2015 TIME Magazine's TIME 100 list of the 100 most influential people in the world. After serving as a member of the Yale University faculty for eight years, during which time she was promoted to Henry Ford II Professor of Molecular Biophysics and Biochemistry, she joined the UC Berkeley faculty in 2002. Dr. Doudna earned a B.A. in Biochemistry from Pomona College and a Ph.D. in Biochemistry from Harvard University.

Martin Jinek, Ph.D.

Dr. Jinek is a co-founder of Caribou and an Assistant Professor at the University of Zurich in the Department of Biochemistry. His research focuses on molecular mechanisms that orchestrate cellular regulation through protein-RNA interactions. His studies include biochemical and structural approaches to investigate these processes at the atomic level. Dr. Jinek has contributed significantly to the field of CRISPR biology both through basic discovery and through the invention of new CRISPR-based technologies. He has won both the Human Frontier Science Program Fellowship and the EMBO Long-term Fellowship. Dr. Jinek received a B.A. in Natural Sciences and an M.S. in Chemistry from the University of Cambridge and a Ph.D. in Structural Biology from the University of Heidelberg.

Ami Bhatt, M.D., Ph.D.

Dr. Bhatt is Assistant Professor of Medicine (Hematology) and of Genetics at Stanford University where her research focuses on inspecting, characterizing, and dissecting the microbe-human interface. Dr. Bhatt is also the Director of Global Oncology at the Center for Innovation in Global Health at Stanford and the co-founder of the non-profit organization Global Oncology with the goal of improving cancer outcomes for patients in impoverished settings. Dr. Bhatt earned her M.D. in Medicine and Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco and completed residency and chief residency in Internal Medicine at Brigham and Women’s Hospital. Dr. Bhatt completed her post-doctoral fellowship at the Broad Institute of Harvard and MIT and completed her hematology/oncology fellowship at the Dana-Farber Cancer Institute.

Jeffrey Rathmell, Ph.D.

Dr. Rathmell is Director of the Vanderbilt Center for Immunobiology and serves as the Associate Director of the Institute of Infection, Immunology and Inflammation at the Vanderbilt University Medical Center where he is also the co-leader of the Molecular Pathology and Immunology PhD training program. His studies focus on manipulating mechanisms to control inflammatory diseases and anti-tumor immune responses, and to understand how metabolism is intimately linked to nearly all aspects of cell function. Prior to joining the Vanderbilt University Medical Center, Dr. Rathmell was a member of the Duke Molecular Physiology Institute and was involved with the departments of Pharmacology, Cancer Biology and Immunology. He earned a Ph.D. in Immunology on B cell tolerance and death mechanisms at Stanford University. Dr. Rathmell completed postdoctoral studies at the University of Chicago and the University of Pennsylvania.

Noopur Raje, M.D.

Dr. Raje is a Professor of Medicine at Harvard Medical School, the director of the Center for Multiple Myeloma and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. She is a physician scientist with a primary focus on multiple myeloma and related plasma cell disorders. Dr. Raje has focused on developing new promising therapies for multiple myeloma. Her laboratory efforts are aimed at identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and designing trials to specifically harness these. She is the co-chair of the NCI steering committee for multiple myeloma and a board member of the International Myeloma Society. Dr. Raje received her M.D. from B.J. Medical College at Pune University. She trained in internal medicine at MGH and completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute.

Cameron Turtle, M.B.B.S., Ph.D.

Dr. Turtle is an Associate Member at Fred Hutchinson Cancer Research Center (FHCRC) and an Associate Professor at the University of Washington (UW) in Seattle, WA. He serves as an attending physician on the Hematopoietic Cell Transplant (HCT) Service and the Immunotherapy Service at FHCRC, Seattle Cancer Care Alliance (SCCA) and the UW Medical Center. His research laboratory in the Clinical Research Division at FHCRC is focused on understanding the characteristics of distinct subsets of human CD8+ T cells, their potential utility for tumor immunotherapy, and their role in immune reconstitution after HCT. Dr. Turtle is Principal Investigator and IND sponsor of several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T cell therapy for patients with B cell malignancies. He completed medical training at the University of Sydney, Australia, followed by Fellowships of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia, and a Ph.D. in Immunology.